Skip Nav Destination
Search Results for treat lymphoma leukemia myeloma
1-20 of 4014 Search Results for
treat lymphoma leukemia myeloma
in Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia > Blood
Figure 5 Up-regulation of proteasome pathway and the growth inhibitory effect of proteasome inhibitors on T-ALL cells . (A) GSEA histograms for human T-ALL cells (cell lines or primary clinical samples) representing the “proteasome pathway.” The NES and the nominal P value are indicated. GSI-tr... More about this image found in Up-regulation of proteasome pathway and the growth inhibitory effect of pro...
in 15-Deoxy-Δ 12,14 -prostaglandin J 2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-κB activity and down-regulation of antiapoptotic proteins > Blood
Figure 6. 15d-PGJ 2 inhibits constitutive NF- κ B binding activity and induces apoptosis in different types of B-cell malignancies. (A) Burkitt lymphoma HS-Sultan and BL-41 cells, multiple myeloma U266 and RPMI-8226 cells, and acute leukemia K562 cells (0.5 × 10 6 cell/mL) were treated with ... More about this image found in 15d-PGJ 2 inhibits constitutive NF- κ B binding activity and induces apop...
in Plasmablastic myeloma/leukemia variant of monomorphic posttransplant lymphoproliferative disorder > Blood
A 73-year-old man with a 2-year history of bilateral lung transplantation presented with progressive fatigue, nausea, and night sweats over the past 2 months. Laboratory tests showed abnormal serum components: creatinine, 460.0 µmol/L; lactate dehydrogenase, 3073 U/L; immunoglobulin A (IgA) lambda p... More about this image found in A 73-year-old man with a 2-year history of bilateral lung transplantation p...
in Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death > Blood
Figure 5. ActD treatment induces cell death in human TP53 wt B-cell lymphomas. (A) ActD IC 50 values of a data set with 740 tumor cell lines from the Genomics of Drug Sensitivity in Cancer (GDSC) database ranked by sensitivity to ActD (left) and box plot showing IC 50 values of hematologic ... More about this image found in ActD treatment induces cell death in human TP53 wt B-cell lymphomas. (A...
Daniela Barraco, MD, Terra L. Lasho, PhD, Christy Finke, BS, Aref Al-Kali, MD, Michelle Elliott, MD, Mark R. Litzow, MD, Naseema Gangat, MBBS, Curtis A. Hanson, MD, Ayalew Tefferi, MD, Mrinal M Patnaik, MBBS
Blood (2016) 128 (22): 1989.
... malignancies included: MM (n=1, 8%), diffuse large B-cell lymphoma (n=1, 8%), Waldenström's macroglobulinemia (n=1, 8%), CLL (n=2, 15%) and acute lymphoblastic leukemia (n=1, 8%). Four (31%) patients needed chemotherapy, with outcomes including: complete remission in one case (multiple myeloma), progression...
Bindu Kanapuru, MD, Harpreet Singh, MD, Adrian Myers, Julia A. Beaver, MD, Virginia Elaine Kwitkowski, MS,NP, Ann T. Farrell, MD, Richard Pazdur, MD
Blood (2017) 130 (Suppl_1): 861.
... distributions of <65, 65-74 and ≥ 75 years. The rates of enrollment for patients with chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and lymphomas (Hodgkin's and non-Hodgkin's lymphoma excluding CLL) were compared with the age distribution of incidence cases by site...
Blood (2016) 128 (22): 4443.
...). The risk was higher for developing multiple myeloma (SIR 30.8 25-38 AER 67/10,000), leukemia (SIR 3.4, 95% CI; 2-5.2 AER 10/10,000) and non-Hodgkin's lymphoma (NHL) (SIR 3.2, 95 % CI 2.1-4.7 AER 13.4/10,000) in "two-month" survivors of plasmacytoma as compared to general population. The risk of developing...
William Casey Wilson, John O Richards, Gabriela Andrejeva, Benjamin J Capoccia, Robyn J Puro, Mike J Donio, Ronald R Hiebsch, Arun K Kashyap, Daniel S Pereira
Blood (2021) 138 (Supplement 1): 2277.
... to red blood cells, non-ADCC direct tumor killing and elicits immunogenic cell death and DAMP induction, all in addition to single-agent phagocytosis. In vivo, AO-176 has exhibited broad anti-tumor activity in preclinical xenograft models of multiple myeloma (MM), acute myeloid leukemia, T cell acute...
Sondra L. Downey-Kopyscinski, PhD, Ricardo De Matos Simoes, PhD, Megan Bariteau, BSc, Minasri L. Borah, Sam Bender, Janaka Foneska, Jennifer Roth, Richard Groen, Gina Walter, Manja Friese-Hamim, Samantha M. Goodstal, Michael Sanderson, Constantine S. Mitsiades, MD PhD
Blood (2019) 134 (Supplement_1): 1291.
... "DNA-barcoded" cell lines (PRISM system) from hematologic malignancies, including multiple myeloma (MM), leukemias and lymphomas, which were treated for 48hr with M3258. MM cell lines (9/16) were strongly represented among the sensitive lines which displayed <50% relative cell viability (compared...
Alessandra Pompa, MD, Francesca Guidotti, MD, Anna Ines Gregorini, MD, Maria Cecilia Goldaniga, MD, Francesca Gaia Rossi, MD, Luca Baldini, MD Prof, Agostino Cortelezzi, MD
Blood (2016) 128 (22): 4927.
... in non‐Hodgkin lymphomas (NHL) and especially chronic lymphocytic leukemia (CLL); until now only few cases have been described in patients affected by multiple myeloma (MM) and other plasma cell disorders. The introduction of new drugs, in particular immunomodulatory drugs (IMiDs), could increase...
Dai Chihara, MDPhD, Erich P. Huang, PhD, Shanda R. Finnigan, MPH, RN, Lisa M. Cordes, PharmD, Nebojsa Skorupan, MD, Yoko Korenaga Fukuda, MD, Larry V. Rubinstein, PhD, Naoko Takebe, MD PhD
Blood (2020) 136 (Supplement 1): 18.
... was administered were assessed through likelihood ratio tests of a generalized linear mixed model. Results Overall, 3,308 patients were treated in 161 trials. Median age of the patients was 61 (range: 0-96) and 61% were male. Acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) was the most common enrolled...
John Richards, PhD, Myriam N Bouchlaka, BS,PhD, Robyn J Puro, PhD, Ben J Capoccia, PhD, Ronald R Hiebsch, BS, Michael J Donio, BS, W. Casey Wilson, PhD, Prabir Chakraborty, PhD, Victoria Sung, PhD, Daniel S Pereira, PhD
Blood (2019) 134 (Supplement_1): 1844.
... hematologic cancers in vitro and in vivo. As a single agent, AO-176 not only promotes phagocytosis (15-45%, EC 50 = 0.33-4.1 µg/ml) of hematologic tumor cell lines (acute myeloid leukemia, non-Hodgkin's lymphoma, multiple myeloma, and T cell leukemia) but also directly targets and kills tumor cells (18-46...
Lori S. Muffly, MDMS, Kevin Sheehan, PhD, Randall Armstrong, Keri Tate, PhD, Cynthia Tudisco, Andrew R. Rezvani, MD, David Miklos, MD PhD, Sally Arai, MD, Judith Shizuru, MD PhD, Laura Johnston, Everett Meyer, MD PhD, Wen-Kai Weng, MD PhD, Ginna G. Laport, MD, Robert S Negrin, MD, Sam Strober, Robert Lowsky, MD
Blood (2016) 128 (22): 4615.
... + memory T cell infusion at three dose levels. Median age was 59 years (range, 29 to 70 years). Diagnoses included acute myeloid leukemia (n= 8), non-Hodgkin lymphoma (n= 3), chronic lymphocytic leukemia (n= 1), chronic myeloid leukemia (n=1), multiple myeloma (n=1), and acute lymphoblastic leukemia (n=1...
Feng Jin, PhD, Ming Yin, PhD, Vinay Mandava, Helena Edlund, PhD, Marilee Andrew, PhD, Priti Patel, MD, Eric Masson, PharmD, Nidal Al-Huniti, PhD, Xiaolin Wang, ScD, J. Greg Slatter, PhD
Blood (2017) 130 (Supplement 1): 1268.
.../refractory (R/R) mantle cell lymphoma (MCL). The relationship between acalabrutinib plasma exposure and safety was evaluated in patients with B-cell malignancies that included R/R MCL, chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, multiple myeloma and Waldenström...
Peter U. Park, Véronique Blanc, Jutta Deckert, Pascale Lejeune, Laura M. Bartle, Anna Skaletskaya, Michele F. Mayo, Chonghui Zhang, Marie-Cécile Wetzel, Daniel J. Tavares, Robert J. Lutz, Thomas Chittenden, Marie-Christine Bissery, John M. Lambert, Victor S. Goldmacher
Blood (2008) 112 (11): 2756.
... for antibody therapeutics for the treatment of various hematological malignancies, including multiple myeloma as well as non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. CD38 is a type II transmembrane glycoprotein...
Seema Singhal, Olga Frankfurt, Andrew Evens, Leo Gordon, Martin Tallman, Stephanie Williams, Jane Winter, David Grinblatt, Lynne Kaminer, Jayesh Mehta
Blood (2007) 110 (11): 5020.
..., this observation continues to remain valid in a series of 91 uniformly-treated patients with hematologic malignancies (19–71 years; median 53; 22% >60 years). 29 patients had acute leukemia, 38 had lymphoma (Hodgkin/NHL) or CLL, and 24 had myeloma. Two-thirds of the patients had refractory disease. Performance...
Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Tayyab Rehan, MBBS, Muhaddis Ejaz Ahmad, MD, Syeda Sabeeka Batool, MBBS, MD, Muhammad Abdullah Yousaf, MBBS, MD, Maaz Ahmed Yusufi, MD, Saif Ur Rehman, MBBS, MD, Sravanthi Kotapati, MBBS, Maimoona Khan, MBBS, Asma Waheed, MBBS, Zainab Ijaz, Awais Ijaz, MD, Faiz Anwer, MD
Blood (2019) 134 (Supplement_1): 4442.
... trial (NCT01029366 / B lymphoma, leukemia / CD19 target / n=20) showed 3 cases (15%) of pneumonia, 1 case each of C Diff, Pseudomonas and salmonella (5%) infections. A Phase 2 trial (NCT02030834, B NHL, CD19 target, n=63) treated patients showed 34% patients experienced infection which included sepsis...
Yukinari Sanada, MD, Kimikazu Yakushijin, MD, Tetsuhiko Nomura, MD, Katsuya Yamamoto, MD, Keiji Kurata, MD, Kei Takenaka, MD, Seiji Kakiuchi, MD, Yoshiharu Miyata, MD, Yoshinori Imamura, MD, Meiko Nishimura, MD, Yohei Funakoshi, MD, Yuriko Iwamoto, MD, Naoko Chayahara, MD, Masanori Toyoda, MD, Yosuke Minami, MD, Naomi Kiyota, MD, Toru Mukohara, MD, Shinichiro Kawamoto, MD, Yohei Shimono, MD, Mitsuhiro Ito, MD, Hiroshi Matsuoka, MD, Hironobu Minami, MD
Blood (2014) 124 (21): 4131.
.... Results: A total of 109 patients (median age 61 years [range 21–89 years]) were enrolled; 55 females and 54 males, 36 hematological malignancies (multiple myeloma [n=15], malignant lymphoma [n=10], chronic myeloid leukemia [n=10], and acute lymphoblastic leukemia [n=1]), 70 solid tumors (breast [n=14...
Utthara Nayar, Jouliana Sadek, Jonathan B Reichel, David Bunn, Denise Hernandez-Hopkins, Peter Barelli, Michelle Sahai, Jennifer Totonchy, Sei Shizuko, Robert Shoemaker, David Warren, Olivier Elemento, Kenneth Kaye, Ethel Cesarman
Blood (2015) 126 (23): 1812.
... be sensitive to 6-ETI, which we documented for primary specimens of PEL, multiple myeloma and other lymphoid malignancies with plasmacytic features, namely plasmablastic lymphoma. A number of nucleoside analogues have been reported to be effective in treating leukemias and B and T cell lymphomas. We performed...
Merav Bar, MD, Barry Storer, PhD, Benedetto Bruno, MD, Parameswaran Hari, MBBS, MD, MRCP, Thomas Chauncey, MD, PhD, Yoshihiro Inamoto, MD, PhD, Paul J. Martin, MD, Rainer Storb, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Mary E.D. Flowers, MD
Blood (2012) 120 (21): 354.
... was given for treatment of chronic myeloid leukemia (n=56), acute myeloid leukemia (n=71), myelodysplastic syndrome (n=25), acute lymphoblastic leukemia (n=21), multiple myeloma (n=23), lymphoma (n=21) and chronic lymphocytic leukemia/lymphoma (n=11). Patients received transplants from HLA-matched related...